FR15C0072I1 - - Google Patents

Info

Publication number
FR15C0072I1
FR15C0072I1 FR15C0072C FR15C0072I1 FR 15C0072 I1 FR15C0072 I1 FR 15C0072I1 FR 15C0072 C FR15C0072 C FR 15C0072C FR 15C0072 I1 FR15C0072 I1 FR 15C0072I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0072(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR15C0072I1 publication Critical patent/FR15C0072I1/fr
Application filed filed Critical
Application granted granted Critical
Publication of FR15C0072I2 publication Critical patent/FR15C0072I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR15C0072C 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti) Active FR15C0072I2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
EP04787096.9A EP1663240B2 (fr) 2003-09-03 2004-09-03 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
PCT/EP2004/052028 WO2005021001A1 (fr) 2003-09-03 2004-09-03 Combinaisons d'une pyrimidine renfermant nnrti avec des inhibiteurs de rt

Publications (2)

Publication Number Publication Date
FR15C0072I1 true FR15C0072I1 (fr) 2015-04-12
FR15C0072I2 FR15C0072I2 (fr) 2019-05-17

Family

ID=34280181

Family Applications (3)

Application Number Title Priority Date Filing Date
FR15C0073C Active FR15C0073I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0071C Active FR15C0071I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0072C Active FR15C0072I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
FR15C0073C Active FR15C0073I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0071C Active FR15C0071I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Country Status (25)

Country Link
US (9) US20080200435A1 (fr)
EP (1) EP1663240B2 (fr)
JP (3) JP5507791B2 (fr)
KR (1) KR20060090658A (fr)
CN (1) CN101060844B (fr)
AP (1) AP2109A (fr)
AU (5) AU2004268390B2 (fr)
BE (1) BE2015C053I2 (fr)
CA (1) CA2537095C (fr)
CY (5) CY2015038I2 (fr)
FI (1) FI1663240T4 (fr)
FR (3) FR15C0073I2 (fr)
HK (1) HK1092698A1 (fr)
HR (1) HRP20150798T4 (fr)
HU (5) HUS1500052I1 (fr)
IL (2) IL173438A (fr)
LT (2) LTC1663240I2 (fr)
LU (3) LU92853I2 (fr)
MX (1) MXPA06002437A (fr)
MY (1) MY169670A (fr)
NL (2) NL300781I2 (fr)
NO (6) NO334877B1 (fr)
NZ (1) NZ545306A (fr)
PL (1) PL1663240T5 (fr)
WO (1) WO2005021001A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JP4822707B2 (ja) 2002-08-09 2011-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの製造方法
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
CN101068597B (zh) * 2004-09-02 2012-04-18 詹森药业有限公司 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
PL1632232T6 (pl) * 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
EP1789139B1 (fr) * 2004-09-02 2012-03-21 Janssen Pharmaceutica NV Hydrochloride de 4-((4-((4-(2-cyanoéthényl)-2,6-diméthylphényl amino -2-pyrimidinyl amino benzonitrile
EP1632232B3 (fr) * 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
EA011036B1 (ru) * 2004-09-02 2008-12-30 Янссен Фармацевтика Н.В. Фумарат 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
SI2051703T1 (sl) * 2005-12-14 2011-01-31 Cipla Ltd Farmacevtski sestavki, ki vsebujejo inhibitorje nukleotidne in nukleozidne reverzne transkriptaze (kot tenofovir in lamivudin) v različnih delih dozirne oblike
DK1981506T6 (da) * 2006-01-20 2021-06-14 Janssen Sciences Ireland Unlimited Co Langtidsbehandling af hiv-infektion med tcm278
US9044509B2 (en) * 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
JP5570999B2 (ja) 2008-01-03 2014-08-13 ユニベルシテ デ―マルセイユ 抗ｈｉｖ治療の際に使用される組成物
MY160360A (en) * 2008-12-24 2017-02-28 Janssen Sciences Ireland Uc Implantable devices for treating hiv
CA2784530C (fr) 2009-12-21 2018-05-22 Janssen R&D Ireland Implant s'eliminant par degradation pour la liberation prolongee d'un principe actif
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
ME01980B (fr) * 2010-11-19 2015-05-20 Gilead Sciences Inc Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil
WO2012125993A1 (fr) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Formes à l'état solide de base rilpivirine et sels de rilpivirine
EP2755959B1 (fr) * 2011-09-16 2018-05-16 Hetero Research Foundation Chlorhydrate de rilpivirine
ES2926068T3 (es) 2012-12-21 2022-10-21 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
ES2970870T3 (es) 2016-10-24 2024-05-31 Janssen Sciences Ireland Unlimited Co Composiciones dispersables
WO2018119371A1 (fr) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Activité anti-flaviviridae d'inhibiteurs de la transcriptase inverse nucléosidiques et non nucléosidiques anti-rétroviraux (nnrtis)
US11234981B2 (en) 2017-04-18 2022-02-01 Cipla Limited Combination therapy for use in treating retroviral infections
WO2019021319A1 (fr) * 2017-07-27 2019-01-31 Cipla Limited Compositions pharmaceutiques
WO2021104487A1 (fr) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition comprenant de la rilpivirine et son utilisation pour le traitement de tumeurs ou du cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
KR0172134B1 (ko) 1990-07-19 1999-02-01 오오쓰까 아끼히코 고형 제제
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JPH07503943A (ja) * 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド 封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質
EP0639971B1 (fr) 1992-05-13 1999-09-22 The Wellcome Foundation Limited Combinaisons therapeutiques
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
EP1214059B1 (fr) 1999-09-21 2005-05-25 Skyepharma Canada Inc. Compositions particulaires, a surface modifiee, de substances biologiquement actives
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
GEP20043285B (en) 2000-03-30 2004-07-26 Bristol Myers Squibb Co Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
CN1487935A (zh) 2000-12-11 2004-04-07 ����ҩƷ��ҵ��ʽ���� 改良型水溶性药物组合物
BR0210518A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de drogas e polìmeros neutros
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CA2465779A1 (fr) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions destinees a la liberation de produits a action continue
JP4822707B2 (ja) 2002-08-09 2011-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの製造方法
WO2004022033A1 (fr) * 2002-09-04 2004-03-18 Microchips, Inc. Technique et dispositif d'apport commande d'hormone parathyroide
CA2505130C (fr) 2002-11-08 2009-10-06 Glaxo Group Limited Compositions pharmaceutiques
AP1927A (en) 2002-11-15 2008-12-10 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20070021449A1 (en) 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
BRPI0511900A (pt) 2004-06-08 2008-01-22 Vertex Pharma composições farmacêuticas
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP1632232B3 (fr) 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
KR20130030305A (ko) 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US20060269475A1 (en) * 2005-04-11 2006-11-30 Ryu Wonhyoung Multi-layer structure having a predetermined layer pattern including an agent
US20090142401A1 (en) 2005-06-07 2009-06-04 Leah Elizabeth Appel Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
WO2007014393A2 (fr) 2005-07-28 2007-02-01 Isp Investments Inc. Efavirenz amorphe et methode de production
DK1981506T6 (da) 2006-01-20 2021-06-14 Janssen Sciences Ireland Unlimited Co Langtidsbehandling af hiv-infektion med tcm278
CL2007001847A1 (es) 2006-06-23 2008-02-08 Tibotec Pharm Ltd Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih.
US20080081064A1 (en) * 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2175857B1 (fr) 2007-07-12 2013-09-11 Janssen R&D Ireland Forme cristalline de (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-diméthylphényl]amino]-2-pyrimidinyl]amino]benzonitrile
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
WO2010047819A1 (fr) * 2008-10-24 2010-04-29 Concert Pharmaceuticals, Inc. Dérivés d'hydroxyéthylaminosulfonamide

Also Published As

Publication number Publication date
HUS1500053I1 (hu) 2016-03-29
HUS1500052I1 (hu) 2016-03-29
CY2015038I1 (el) 2016-08-31
JP5507791B2 (ja) 2014-05-28
NO2016025I1 (fr) 2016-12-20
CY2015040I1 (el) 2016-08-31
EP1663240B1 (fr) 2015-04-22
US8841310B2 (en) 2014-09-23
CA2537095C (fr) 2012-05-29
CY2015039I2 (el) 2016-08-31
FR15C0073I2 (fr) 2016-02-12
NO2014032I1 (no) 2015-01-05
HRP20150798T1 (hr) 2015-09-11
US20080200435A1 (en) 2008-08-21
US20200171027A1 (en) 2020-06-04
NL300781I1 (fr) 2016-04-19
US20190216807A1 (en) 2019-07-18
NO334877B1 (no) 2014-06-23
NL300768I1 (fr) 2015-12-16
CA2537095A1 (fr) 2005-03-10
CY2016049I2 (el) 2017-07-12
LU92853I2 (fr) 2015-12-21
NO20061374L (no) 2006-03-27
FR15C0072I2 (fr) 2019-05-17
LTPA2016044I1 (lt) 2017-01-10
NZ545306A (en) 2009-11-27
CY2015039I1 (el) 2016-08-31
US20220008417A1 (en) 2022-01-13
LTPA2016045I1 (lt) 2017-01-10
AP2006003551A0 (en) 2006-04-30
AU2016210733A1 (en) 2016-08-25
AP2109A (en) 2010-02-26
CY2016048I2 (el) 2017-07-12
AU2004268390A1 (en) 2005-03-10
EP1663240B2 (fr) 2023-03-01
MXPA06002437A (es) 2006-06-20
AU2004268390B2 (en) 2011-03-31
AU2014203484A1 (en) 2014-07-17
IL213104A0 (en) 2011-07-31
US20170100398A1 (en) 2017-04-13
IL173438A0 (en) 2006-06-11
JP5820045B2 (ja) 2015-11-24
HUS1600059I1 (hu) 2017-02-28
NO2014032I2 (no) 2014-12-18
PL1663240T3 (pl) 2015-10-30
NO2014030I1 (no) 2015-01-05
JP2007520443A (ja) 2007-07-26
FR15C0071I1 (fr) 2015-04-12
LU92855I2 (fr) 2015-12-21
AU2011201123A1 (en) 2011-04-07
IL173438A (en) 2012-03-29
IL213104A (en) 2016-02-29
JP2012051915A (ja) 2012-03-15
CY2015040I2 (el) 2016-08-31
NO2016026I1 (no) 2016-12-20
EP1663240A1 (fr) 2006-06-07
CN101060844A (zh) 2007-10-24
CN101060844B (zh) 2012-01-04
AU2011201123B2 (en) 2013-10-10
MY169670A (en) 2019-05-08
BE2015C053I2 (fr) 2023-12-14
LTC1663240I2 (lt) 2022-05-25
US20150283135A1 (en) 2015-10-08
HK1092698A1 (en) 2007-02-16
PL1663240T5 (pl) 2024-02-26
US20100029591A1 (en) 2010-02-04
FR15C0071I2 (fr) 2016-02-12
WO2005021001A1 (fr) 2005-03-10
LU92854I2 (fr) 2015-12-21
KR20060090658A (ko) 2006-08-14
NL300781I2 (fr) 2016-04-19
HUS1500054I1 (hu) 2016-03-29
FI1663240T4 (fi) 2023-04-25
US20180228800A1 (en) 2018-08-16
NL300768I2 (nl) 2023-08-09
FR15C0073I1 (fr) 2015-04-12
AU2014203484B2 (en) 2016-09-29
JP2015044839A (ja) 2015-03-12
NO2014030I2 (no) 2014-12-18
NO2014031I2 (no) 2014-12-18
CY2016048I1 (el) 2017-07-12
CY2016049I1 (el) 2017-07-12
HRP20150798T4 (hr) 2023-06-09
AU2016210733B2 (en) 2018-11-08
CY2015038I2 (el) 2016-08-31
US20140349971A1 (en) 2014-11-27
HUS1600058I1 (hu) 2017-02-28
AU2019200813A1 (en) 2019-02-28
NO2014031I1 (no) 2015-01-05

Similar Documents

Publication Publication Date Title
FR15C0073I1 (fr)
BE2013C075I2 (fr)
BE2013C070I2 (fr)
BE2013C067I2 (fr)
BE2013C038I2 (fr)
BE2013C036I2 (fr)
BE2013C034I2 (fr)
BE2011C030I2 (fr)
BE2012C053I2 (fr)
JP2004045396A5 (fr)
JP2004046124A5 (fr)
JP2004007502A5 (fr)
AU2002316511A1 (fr)
AU2002253451A1 (fr)
AU2002329412A1 (fr)
AU2002327736A1 (fr)
AU2002327042A1 (fr)
AU2002324323A1 (fr)
AU2002333044A1 (fr)
AU2002322913A1 (fr)
AU2002321535A1 (fr)
AU2002318342A1 (fr)
AU2002337949A1 (fr)
AU2002316235A1 (fr)
AU2002311957A1 (fr)